Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Growth in Short Interest

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 269,200 shares, a growth of 383.3% from the January 15th total of 55,700 shares. Based on an average daily volume of 691,100 shares, the days-to-cover ratio is currently 0.4 days. Approximately 14.6% of the shares of the company are short sold.

Vincerx Pharma Price Performance

Shares of VINC traded down $0.08 during trading hours on Wednesday, reaching $1.26. 129,305 shares of the company’s stock traded hands, compared to its average volume of 898,867. The firm has a market capitalization of $2.82 million, a price-to-earnings ratio of -0.06 and a beta of 1.37. Vincerx Pharma has a twelve month low of $1.24 and a twelve month high of $187.44. The business’s fifty day simple moving average is $3.32 and its two-hundred day simple moving average is $8.06.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.